Novartis cuts PhII obesity candidate as it finalizes Sandoz spinoff

Amber Tong

Novartis shelved a Phase II program it was testing for obesity-related diseases after finding a lack of efficacy, the pharma giant disclosed Tuesday in its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis cuts PhII obesity candidate as it finalizes Sandoz spinoff

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

No­var­tis cuts PhII obe­si­ty can­di­date as it fi­nal­izes San­doz spin­off

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Novartis cuts PhII obesity candidate as it finalizes Sandoz spinoff